Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases

由 Al Jarroudi, Ouissam, Ulusakarya, Ayhan, Almohamad, Wathek, Afqir, Said, Morere, Jean-Francois
發表在 Cureus (2020)

Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas

由 Machover, David, Almohamad, Wathek, Castagné, Vincent, Desterke, Christophe, Gomez, Léa, Gaston-Mathé, Yann, Boucheix, Claude, Goldschmidt, Emma
發表在 Sci Rep (2021)

Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience

由 Al jarroudi, Ouissam, Chaabouni, Hamed, Ulusakarya, Ayhan, Almohamad, Wathek, Gumus, Yusuf, Goldschmidt, Emma, Afqir, Said, Morère, Jean‐francois
發表在 Clin Case Rep (2021)

Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma

由 Ulusakarya, Ayhan, Teyar, Nahla, Karaboué, Abdoulaye, Haydar, Mazen, Krimi, Sarra, Biondani, Pamela, Gumus, Yusuf, Chebib, Amale, Almohamad, Wathek, Morère, Jean-François
發表在 Medicine (Baltimore) (2019)

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer

由 Ulusakarya, Ayhan, Karaboué, Abdoulaye, Ciacio, Oriana, Pittau, Gabriella, Haydar, Mazen, Biondani, Pamela, Gumus, Yusuf, Chebib, Amale, Almohamad, Wathek, Innominato, Pasquale F.
發表在 BMC Cancer (2020)